Clinical Trial Update: NM-IL-12 (rHuIL-12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy [Phase 2]

View source ↗

Summary

This document provides a Phase 2 clinical trial update for NM-IL-12 (recombinant human interleukin-12) in relapsed/refractory diffuse large B-cell lymphoma pati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• NM-IL-12 (rHuIL-12) (recombinant human interleukin-12)

Snippet

Sponsor: Neumedicines Inc. | Conditions: Lymphoma, Large B-Cell, Diffuse (DLBCL) | Phase 2 | Status: UNKNOWN